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Abstract
The p53 tumor suppressor invokes cellular responses to stressful stimuli by coordinating distinct gene expression programs.
This function relies heavily on the ability of p53 to function as a transcription factor by binding promoters of target genes in
a sequence specific manner. The DNA binding activity of the core domain of p53 is subject to regulation via post-
translational modifications of the C-terminal region. Here we show that the ubiquitin specific protease, USP7 or HAUSP,
known to stabilize p53, also regulates the sequence-specific DNA binding mediated by the core domain of p53 in vitro. This
regulation is contingent upon interaction between USP7 and the C-terminal regulatory region of p53. However, our data
suggest that this effect is not mediated through the N-terminal domain of USP7 previously shown to bind p53, but rather
involves the USP7 C-terminal domain and is independent of the deubiquitylation activity of USP7. Consistent with our in
vitro observations, we found that overexpression of catalytically inactive USP7 in cells promotes p53 binding to its target
sequences and p21 expression, without increasing the levels of p53 protein. We also found that the USP7 C-terminal domain
was sufficient for p21 induction. Our results suggest a novel mode of regulation of p53 function by USP7, which is
independent of USP7 deubiquitylating activity.
Citation: Sarkari F, Sheng Y, Frappier L (2010) USP7/HAUSP Promotes the Sequence-Specific DNA Binding Activity of p53. PLoS ONE 5(9): e13040. doi:10.1371/
journal.pone.0013040
Editor: Mikhail V. Blagosklonny, Roswell Park Cancer Institute, United States of America
Received June 8, 2010; Accepted September 3, 2010; Published September 27, 2010
Copyright:  2010 Sarkari et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a Canadian Cancer Society Research Grant to L.F. and a National Cancer Institute of Canada studentship to F.S. L.F. is a tier
1 Canada Research Chair in Molecular Virology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lori.frappier@utoronto.ca
Introduction
The tumor suppressor p53, often referred to as the guardian of
the genome, functions by integrating signals of cellular stress and
controlling cell fate [1]. Depending on the nature of stimulus and
the extent of cellular stress, p53 orchestrates responses that range
from transient cell cycle arrest, allowing for DNA repair and cell
survival, to programmed cell death or apoptosis [2]. Aberrant
function of a tumor suppressor like p53 would lead to unchecked
growth and onset of cancer. It is thus not surprising that
inactivation of p53 function through either mutations or
interactions with cellular or viral proteins is one of the most
common oncogenic events in human cancers [1,3,4].
p53 fulfills its tumor suppressive function primarily by acting as
a transcription factor. p53 binds DNA as a dimer of dimers in a
sequence specific manner to a consensus site comprising of two
decamer repeats of 59-PuPuPuC(A/T)(T/A)GPyPyPy-39 (where
Pu is a purine and Py is a pyrimidine) separated by 0 to 13 base
pairs [5]. p53 predominantly activates transcription of target
genes, though evidence of transcriptional repression by p53 also
exists [6]. A growing body of work has also unearthed a cytosolic
and transcription-independent function of p53 [7]. In this role,
p53 interacts with anti apoptotic and pro-apoptotic BCL family of
proteins and helps bring about permeablization of the outer
mitochondrial membrane, which subsequently results in apoptosis.
Though cytoplasmic functions of p53 are not strictly dependent on
p53 transcription activation, transcriptional regulation by p53 is
still tied to the cytosolic functions of p53 since some of the BCL
family members are direct transcriptional targets of p53 [7]. The
importance of DNA binding and therefore transcriptional control
by p53 is further highlighted by the observation that many of the
p53 mutations found in tumors are clustered in the DNA binding
domain [8] (UMD p53 database 2008_R2; http://p53.free.fr/).
The p53 protein is organized in distinct functional and
structural domains. Transcription activation is mediated by the
N-terminal transactivation domain (residues 1–70). Residues 94–
292 form the DNA-binding domain, which binds DNA in a
sequence-specific manner and is also referred to as the core
domain. Further downstream is the oligomerization region
(residues 320–360) which mediates p53 tetramerization, the
functional form of p53 as a transcription factor. The extreme C-
terminus of p53 (residues 360–393) forms a lysine and arginine
rich basic region and possesses sequence-nonspecific DNA binding
activity that is independent of the core DNA binding domain. This
region, also known as the regulatory region, was initially thought
to negatively regulate the DNA binding activity of the core
domain. This notion was based on the observations that deletion
and post-translational modifications of the regulatory region or its
interaction with an antibody (PAb 421) directed at a C-terminal
epitope, lead to an increase in DNA binding by the core domain
[9,10,11,12,13]. It was proposed that these modifications of the C-
terminal regulatory domain of p53 induce an allosteric confor-
mational change that switches the core domain from a latent form
with low affinity for its DNA binding site to an active form with
higher affinity for DNA [9,14,15]. These studies however mostly
relied on short stretches of naked DNA containing p53-binding
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NMR-study that showed that full length p53 (latent form) and p53
lacking the C-terminal regulatory domain (active form) were
identical in structure [16].
More recent lines of evidence have suggested a positive role for
the regulatory region in DNA binding by the core domain. First, a
deletion mutant lacking the C-terminal region (p53D30) shows
weaker DNA binding ability than WT p53, when longer molecules
of DNA are used [17]. Second, efficient recognition of target sites
in circular DNA or stemloop structures requires the C-terminal
region of p53 [18,19]. Third, it was shown that the C-terminal
region of p53, through its nonspecific DNA binding activity, helps
p53 slide along stretches of DNA [20,21]. Linear diffusion along
DNA allows the p53 core domain to sample sequences and find its
target sites. Thus, the p53 C-terminus positively contributes to
sequence specific DNA binding by the p53 core domain through
mechanisms that are not fully understood.
An important regulator of p53 function is the herpesvirus
associated ubiquitin specific protease, HAUSP or USP7, which
deubiquitylates p53 and protects it from proteasome-mediated
degradation [22]. Deletion analyses have shown that the C-
terminal regulatory region of p53 (residues 351–382) binds USP7
and that the N-terminal domain (residues 53–208) of USP7 is
sufficient for this interaction [23,24]. Crystal structures of the
USP7 N-terminal domain showed that it is a TRAF domain and
that a groove on its surface forms interaction with p53 and other
targets [25,26,27]. USP7 was originally identified as a binding
partner of the ICP0 protein from herpes simplex virus [28] and
was shown to interact with another herpesvirus protein, EBNA1 of
Epstein-Barr virus (EBV) [29]. We have shown that EBNA1 can
alter cellular processes, including p53 function, through its
interaction with USP7 [25,30]. However, EBNA19s more
traditionally known functions rely on its DNA binding activity to
mediate replication and segregation of the EBV genome and
transactivation of viral genes [31]. Interestingly, we have shown
that USP7 stimulates the DNA binding activity of EBNA1 and is
important for transcriptional activation by EBNA1 at the latent
origin of EBV replication [32]. However it was unclear whether
this ability of USP7 to stimulate DNA binding activity was only
relevant for EBNA1 or might also apply to other USP7 targets.
Given that USP7 binds the C-terminal domain of p53 [24] and
that this domain regulates DNA binding by the p53 core domain,
we asked whether USP7 affects the DNA binding activity of p53
and downstream p53 functions. In this study, we discuss
observations that support a role of USP7 in regulating p53 DNA
binding. This provides a novel aspect of p53 regulation by USP7,
since it is independent of p53 deubiquitilyation.
Results
Effect of USP7 on DNA Binding by p53
To assess the effect of USP7 on p53 DNA binding, we conducted
electrophoretic mobility shift assays (EMSAs) using a Cy-5 labeled
consensus p53 binding sequence as a probe and a version of p53
spanning the core DNA binding and the C-terminal regulatory
regions (p5382–393) but lacking the transactivation domain,
(Figure 1A). Purified p5382–393 was incubated with the labeled
DNA in the presence of USP7 or BSA as a negative control. This
version of p53 is termed the latent form since in EMSAs it exhibits
decreased sequence-specific DNA binding, as characterized by the
smearing of DNA-protein complexes and, at high protein concen-
trations, a small amount of a discreet band in the shifted DNA probe
(see Figure 1B, lanes 2–5 and Figure 1C lanes, 6–8). In contrast, in
the presence of USP7, p5382–393 formed DNA complexes that
migrated as distinct bands as is characteristic of sequence-specific
DNA binding (Figure 1B, lanes 6–9 and Figure 1C lanes 3–5).
Experiments were performed both by titrating p53 with a fixed
amount of excess USP7 (Figure 1B) and by incubating a fixed
amount of p53 with increasing amounts of USP7 (Figure 1C), with
similar results. The latter experiment showed that USP7 had a
dose-dependant stimulatory effect on the DNA binding ability of
p5382–393 while the BSA negative control had little to no effect
(Figure 1C). Neither USP7 nor BSA detectably bound the DNA
probe under these conditions, even at the highest concentrations
(Figure 1C, lanes 9 and 10). These results show that USP7 stimulates
the DNA binding activity of p53.
USP7 Stimulates p53 DNA Binding Through Interactions
with the p53 C-terminal Regulatory Region
To test whether USP7 binding was responsible for the
stimulatory effect on sequence-specific DNA binding by p53, we
conducted EMSAs using another version of p53, p5382–360
(Figure 1A), which differs from p5382–393 in that it lacks the C-
terminal regulatory region responsible for both USP7 binding [23]
and nonspecific DNA binding. This version is termed the active
form of p53 as it lacks autoinhibition from the C-terminal region.
As expected, p5382–360 efficiently binds DNA, at concentrations
much lower than that used for latent p53, as indicated by the
distinct shifts in the mobility of the DNA probe (Figure 1D, lanes
2–5). While, the active p5382–360 binds better than the latent form,
p5382–393, its DNA binding was hardly affected by USP7
(Figure 1D, lanes 6–9), indicating that USP7 acts through a
specific interaction with the p53 regulatory region.
USP7 C-terminal Sequences Stimulate p53 DNA Binding
It has been shown that the N-terminal domain of USP7 (USP7-
NTD) is sufficient to interact with p53 [24]. Therefore we
examined whether the interaction mediated by USP7-NTD
(shown in Figure 2A) was sufficient to stimulate the DNA binding
activity of p53. To this end, we performed EMSAs with latent
p5382–393 in the presence and absence of USP7-NTD. Surprisingly
the USP7-NTD did not stimulate sequence-specific DNA binding
by p5382–393, as the p53-DNA complexes migrated as smears
rather than discreet bands both in the presence and absence of the
USP7-NTD (Figure 2B). This suggests that interactions occur
between p53 and USP7 regions other than the USP7-NTD, which
is responsible for the stimulatory effect of USP7 on p53 DNA
binding.
USP7 C-terminal regions downstream of the catalytic domain
are also known to mediate some protein interactions [33,34]
including weak interactions with p53 [24]. Therefore we tested
whether the USP7-CTD (amino acids 560–1102 as shown in
Figure 2A) could account for the effect of USP7 on p53 DNA
binding by assaying the DNA binding activity of p5382–393 in the
presence and absence of this USP7 domain (Figure 2C). Similar to
what we observed with full-length USP7, the USP7-CTD
stimulated sequence-specific DNA binding by p53, as compared
to the BSA control, suggesting that it is largely responsible for the
p53-USP7 interaction that results in increased p53 sequence-
specific DNA binding.
USP7 Promotes p53 DNA-binding in vivo
We next investigated whether USP7 stimulates p53 DNA-
binding in cells. To this end, p53-negative H1299 cells were
transfected with a plasmid expressing p53 alone, with or without a
plasmid expressing WT USP7 or a catalytically inactive mutant of
USP7, C223S. C223S binds p53 but does not stabilize it due to the
USP7 Increases p53 DNA Binding
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destabilize p53 through a dominant negative effect [24]. The use
of this USP7 mutant ensured that any stimulation of p53 function
was not due to increased levels of p53. Promoter occupancy by
p53 was measured by chromatin immunoprecipitation (ChIP)
using p53 antibody and quantitative PCR of various p53 target
sequences (p21, Mdm2, Bax and PIG3) 24 hours post transfection.
p53 immunoprecipitates were enriched for all p53 target
promoters tested, with the highest level of binding detected at
the p21 promoter (Figure 3). Little to no DNA was recovered for
the negative control GAPDH region. Consistent with our in vitro
results, co-expression of USP7 or C223S stimulated binding of p53
to all the p53-responsive promoters tested and not the non-specific
GAPDH control. The finding that C223S stimulated p53-DNA
Figure1.EffectofUSP7ontheDNAbindingactivityofp53invitro.(A)Schematic representationofthep53 proteinsusedinthisstudyshowing
the transactivation (Trans), DNA binding core, tetramerization (Tet) and USP7-binding and regulatory (USP7/Reg) regions. (B) EMSA showing titration of
latent p5382–393 in the presence of 20 mM of BSAnegative control (lanes2–5) or 20 mM USP7 (lanes6–9). (C)EMSA performed with fixed amount (12 mM)
of p5382–393 and with 5 mM, 10 mMo r2 0mM of USP7 (lanes 3–5) or BSA (lanes 6–8). Incubation of 20 mM of USP7 alone or BSA alone with labeled probe
in theabsence ofp53is also shown (lanes9 and10). (D)EMSA showing titration ofactivep5382–360, in theabsence (lanes2–5)or presenceofUSP7 (lanes
6–9). Quantification of the discreet shifted bands for parts B,C and D are shown in the graphs, with USP7 in black and BSA in grey.
doi:10.1371/journal.pone.0013040.g001
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this stimulation is independent of p53 stabilization.
USP7 can Stimulate p53 Function Independent of its
Catalytic Activity
The results above show that USP7 promotes binding of p53 to
its target DNA. Since the most striking results were obtained for
the p21 promoter, we focused further studies on p53 function on
inductions of the p21 gene. First, we tested whether USP7 could
stimulate p53 function in a ubiquitin-independent manner during
conditions of cellular stress such as DNA damage. To this end we
measured induction of p21 expression in U2OS cells, which
express wild type p53. p21 protein levels are normally low,
however in response to DNA damage, p53 activates transcription
of the gene encoding p21 and hence increases p21 protein levels.
U2OS cells were transfected with either an empty vector or a
vector expressing C223S. Since C223S expression does not
stabilize p53, the use of this USP7 mutant ensured that any
stimulation of p53 function was not due to increased levels of p53.
Etoposide treatment of U2OS cells transfected with the empty
vector led to stabilization of p53, which was accompanied by
accumulation of p21 (Figure 4A, compare lane 1 to 2–4). p53
stabilization was diminished in C223S-transfected cells, consistent
with its dominant negative effects (Figure 4A; compare lanes 3 and
4 to lanes 7 and 8). However expression of p21 was increased by
C223S both before and, more dramatically, after etoposide
treatment (Figure 4A, top panels, compare lanes 1–4 to 5–8).
These observations suggest that after induction of DNA damage,
in addition to stabilizing p53, USP7 can also stimulate p53 DNA-
binding and serve a dual role in p53 regulation under conditions of
cellular stress.
Next we tested whether USP7 enhanced p53 function by
examining the induction of p21 in H1299 cells after transfection of
a p53-expressing plasmid alone or in combination with a plasmid
expressing either WT USP7 or a USP7 mutant (Figure 4B). At the
levels of p53 expressed, little to no p21 expression was observed in
the p53 only sample (Figure 4B, lane 2). Consistent with the ChIP
results, coexpression of WT USP7 or C223S led to induction of
p21 (lanes 3 and 4). We also tested the effect of the USP7-NTD
and USP7-CTD on p21 expression. The USP7-CTD stimulated
p21 expression, whereas minimal effect was seen with USP7-NTD
(lanes 5 and 6). These results are consistent with the in vitro
observation that the CTD of USP7 is sufficient to stimulate p53-
DNA binding, and together these observations suggest that the
stimulation of p53 DNA-binding by USP7 leads to enhanced p53
function.
Figure 2. Effects of USP7 NTD and CTD on p53 DNA binding. (A) Schematic representation of the USP7 proteins used in this study showing
the N-terminal (NTD) or TRAF domain, central catalytic (CAT) and C-terminal (CTD) domains. The position of the C223S point mutation that inactivates
the catalytic domain is also shown. (B–C) EMSAs showing titration of latent p5382–393, in the presence or absence of 20 mM USP7-NTD (B) or 20 mM
USP7-CTD (C). Quantification of the discreet shifted bands are shown in the graphs, with USP7 in black and BSA in grey.
doi:10.1371/journal.pone.0013040.g002
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to promote DNA binding by p53 in vitro and p21 expression in
cells, suggesting that the USP7-CTD contributes to transcriptional
activation by p53. To test this more directly, we cotransfected
H1299 cells with a reporter plasmid in which expression of the
luciferase gene is under control of the p21 promoter, along with a
p53-expression plasmid or corresponding empty plasmid
(Figure 4C). The reporter construct alone or the p53 expression
vector alone showed minimal to no luciferase activity, while
expression of p53 with the reporter construct gave luciferase
activity above background. However coexpression of USP7-CTD
with p53 resulted in a 5-fold increase in luciferase activity,
indicating that the USP7-CTD can stimulate p53 transactivation
from the p21 promoter.
Discussion
The DNA-binding ability of p53 is critical to its function as a
transcription factor and thus as a tumor suppressor. The
significance of sequence-specific DNA binding for p53 tumor
suppressor function is highlighted by the substantial number of
tumor-associated mutations in the core DNA-binding domain
[35]. An important determinant of DNA binding by the core
domain is the autoregulation of this activity by the C-terminal
regulatory domain of p53. The C-terminal domain is heavily
modified post-translationally and these modifications affect the
ability of p53 to bind DNA [36,37]. Here we propose that binding
to the ubiquitin specific protease, USP7, is yet another means of
regulating this property of p53.
Full length p53, with the core DNA binding domain and the C-
terminal domain intact, is referred to as the latent form, since it
Figure 3. USP7 promotes p53 DNA-binding in vivo. H1299 cells
were either transfected with an empty plasmid (Vector) or transfected
with a p53-expressing plasmid alone or in combination with constructs
expressing either WT myc-tagged USP7 (+USP7 WT) or myc-tagged
C223S (+C223S). p53 occupancy of various promoters in transfected
cells was measured by chromatin immunoprecipitation using a p53
antibody and Q-PCR of the target sequences indicated. GAPDH was
used a negative control region for Q-PCR. Results were normalized to
p53 levels determined for each sample by Western blotting (see
Figure 4B for an example) to adjust for any small variations in p53 levels.
doi:10.1371/journal.pone.0013040.g003
Figure 4. Catalytically inactive USP7 stimulates p53 function. (A) U2OS cells were transfected with an empty vector or vector expressing the
myc-tagged C223S mutant of USP7 and treated with etoposide for 0, 1, 2 or 4 hours as indicated. Equal amounts of cell lysates were analyzed for
protein expression by western blotting using the indicated antibodies where actin is the loading control. (B) H1299 cells were either transfected with
an empty plasmid (Vector) or transfected with a p53-expressing plasmid alone or in combination with constructs expressing myc-tagged USP7 and
USP7 mutants as indicated. 24 hours post-transfection, cells were lysed and protein levels were measured by Western blotting using the antibodies
indicated. The higher p53 band in lane 4 corresponds to monoubiquitylated p53 which becomes apparent due to the dominant-negative effects of
C223S [24]. (C) H1299 cells were transfected with plasmids expressing p53 and myc-tagged USP7-CTD and a luciferase reporter construct in the
combinations indicated. 48 hours post-transfection, cells were lysed and luciferase activity was quantified. The results are shown relative to the p53
plus reporter sample for three independent experiments.
doi:10.1371/journal.pone.0013040.g004
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assays. This effect is attributed to autoinhibition of sequence-
specific DNA binding by the C-terminal domain due to increased
DNA sliding [20,21]. Incubation of latent p53 with USP7 in
EMSAs stimulated sequence-specific DNA binding by latent p53,
suggesting that USP7-binding can reverse this autoinhibition.
DNA binding by a C-terminal deletion mutant of p53, p5382–360,
which lacks the USP7 binding sequences, was not stimulated by
USP7, suggesting that binding to USP7 is required for this effect.
The observation that USP7 stimulates sequence-specific DNA
binding by p53 through interaction with the C-terminal regulatory
region of p53 further support the notion that this region of p53 is a
positive regulator of p53 DNA-binding and p53 function [20].
Since the p53 regulatory region contributes to DNA interactions
by increasing the sliding of p53 on DNA and such sliding has been
suggested to result in decreased detectable binding to short DNA
fragments (such as used in our in vitro studies), it is likely that USP7
interactions with p53 C-terminal sequences result in decreased
DNA sliding [20].
The USP7-NTD, which is sufficient to bind p53, had no
obvious effect on the DNA-binding activity of p53. While the
interaction of p53 with the USP7-NTD is important for
deubiquitylation and stabilization of p53, the results here suggest
that interactions mediated by other regions of USP7 are important
for the effect on p53 DNA binding. In support of this assumption,
we found that the USP7-CTD can stimulate DNA binding by
latent p53. The results suggest that the USP7-CTD can also
mediate p53 interactions and that this interaction is largely
responsible for stimulating the sequence-specific DNA binding
activity of p53. This is in keeping with initial reports by Li et al
[24] that weak interaction between p53 and the USP7 C-terminal
region (637–1102) could be detected in GST pull-down assays. It
should be noted that, the USP7-CTD is also known to mediate
interactions with other proteins including FOXO [34] and the
ICP0 protein of herpes simplex virus [33].
This investigation was prompted by our previous observation
that USP7 stimulated the DNA binding activity of the EBV
EBNA1 protein [32]. There are similarities and subtle differences
in how USP7 contributes to the DNA binding activity of these two
very different proteins. The USP7-NTD has been shown to be
sufficient for binding both p53 and EBNA1 [25,33]. However,
while the USP7-NTD can stimulate DNA binding by EBNA1, it
had no effect on p53 DNA binding. For EBNA1, the USP7-NTD
did not stimulate DNA binding to the same degree as the full
length USP7, suggesting that the USP7-CTD also contributes to
this effect. Therefore, for both EBNA1 and p53, the data suggest
that USP7 regions other than the NTD can contribute to
interactions that stimulate DNA binding (albeit to differing
degrees). Another difference in how USP7 affects DNA binding
by EBNA1 and p53 may be in the degree to which it remains
associated with the DNA complex. USP7 forms a ternary complex
with EBNA1 on DNA and EBNA1 can recruit USP7 to EBNA1
binding sequences in the EBV genome where it affects histone
H2B ubiquitylation [32]. This ternary complex is evident in vitro by
the decreased mobility or supershift of EBNA1-DNA complexes
by USP7 in EMSAs [32]. In contrast, p53-DNA complexes
migrated similarly in the presence or absence of USP7 (compare
shifted bands in Figure 1B), suggesting that USP7 does not remain
stably associated with DNA-bound p53. However, this merits
further investigation, particularly in vivo where the interaction
might be stabilized by the presence of additional proteins and/or
DNA sequences.
Additionally, we showed that USP7 overexpression consistently
promoted p53 binding to several p53 response elements in cells.
Interestingly, the catalytically inactive USP7, C223S, which does
not stabilize p53, promoted p53 DNA-binding in cells just as well
or better than WT USP7. In line with these results, we found that
overexpression of C223S, leads to increased p21 levels compared
to control cells before and after etoposide treatment, without
increasing p53 levels. This is consistent with stimulation of p53
binding to the p21 promoter resulting in enhanced p21 expression.
More detailed analysis of the effect of USP7 mutants on p53-
dependent p21 expression in cells revealed that the USP7-NTD,
shown previously to bind p53, had negligible effect on p21
expression, whereas the USP7-CTD was sufficient to promote
p53-dependent p21 expression. These results are consistent with
our in vitro observations that the USP7-NTD does not stimulate
p53-DNA binding and that this stimulation is mediated by the
USP7-CTD. Taken together, our results show that USP7 can
promote p53 function in a manner that is independent of the
interaction through the USP7-NTD and deubiquitylation by the
catalytic domain. On that note, we have recently shown that USP7
promotes the degradation of PML proteins (whose gene is
activated by p53) by a mechanism that is independent of its
catalytic activity [38]. Clearly the role of USP7 in regulating the
p53 pathway is more complicated than its previously established
role as a deubiquitylating enzyme.
Materials and Methods
p53 and USP7 Constructs and Purification
Constructs expressing p53 mutants for purification and the
subsequent purification of p53 proteins are described previously
[16].USP7proteinsforinvitrostudieswereexpressedand purified as
described by Holowaty et al [29]. To generate the pCANmycUSP7
plasmid use for expression in human cells, USP7 cDNA was PCR
amplified from the pET3a-USP7 plasmid (a gift from Roger
Everett). The amplified fragment was ligated intoHindIII and XbaI
sites of the pcDNA3.1-derived plasmid, pCANmyc. pCAN-
mycC223S plasmid was generated by QuickChange mutagenesis
of pCANmycUSP7 using the following primers: 59CAGGGAGC-
GACTTCTTACATGAACAGCCTG39 and 59CAGGCTGTT-
CATGTAAGAAGTCGCTCCCTG39. USP7 NTD and USP7
CTD fragments were generated by PCR-amplification of the
sequences encoding these domains from pCANmycUSP7 using the
primers 59CGCCGCAAGCTTCCGAAAAAAAAAAAACGCA-
AAGTGATGAACCACCAGCAGCAGC 39 and 59 CCGGGA-
TCCTCACTTTGAATCCCACGCAACTCC 39 for the NTD
and59CGCCGCAAGCTTCCGAAAAAAAAAAAACGCAAAG-
TGGAAGCCCATCTCTATATGCAAG 39 and 59GCGGGAT-
CCTCAGTTATGGATTTTAATGGCC 39 for the CTD. The
sequence coding for the SV40 T antigen nuclear localization signal
was included in the 59 primers to generate an in-frame NLS at the
N-terminus of each domain. Amplified fragments were ligated into
pCMVmyc [39] between HindIII and BamHI sites.
Electrophoretic Mobility Shift Assays (EMSAs)
The labeling of DNA double stranded probes and EMSAs were
performed according to Ayed et al [16]. Briefly, p53 was incubated
with either BSA or USP7 on ice for 5 minutes prior to incubation
with 8 pmoles of Cy-5 Dye labeled DNA double stranded probe
(GGACATGCCCGGGCATGTCC). Protein-DNA mixes were
further incubated at room temperature for 10 minutes in the
presence of 1 mg salmon sperm competitive DNA and total
reaction volume was brought up to 20 mL using reaction buffer
(20 mM Tris.Cl pH 8.0, 200 mM NaCl). Samples were resolved
on 5% polyacrylamide gels at 4uC at 100 V. Gels were scanned
using a Typhoon 9400 scanner (Amersham) and analyzed using
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was quantified by determining the amount of Cy-5 in a box
containing the discreet shifted band and in the same-sized box at
the same position in each lane.
Western Blots
For Figure 4A, U2OS cells in 10 cm dishes at 80% confluency
were transfected with 10 mg pCANmyc or pCANmycC223S using
Lipfectamine 2000 (Invitrogen). 24 hours post transfection, cells
were either left untreated or treated with 10 mg/mL of etoposide
for 1, 2 and 4 hours. Cells were harvested and lysed in 9 M urea,
5 mM Tris.Cl pH 6.8, sonicated briefly and subjected to
centrifugation for 1 minute at 15,000 rpm in a microcentrifuge.
50 mg of total protein was subjected to SDS-PAGE and transferred
to PVDF membrane (Amersham). For Figure 4B, H1299 cells in
10 cm dishes at 80% confluency were transfected using Lipfecta-
mine 2000 (Invitrogen) with 20 ng of pCDNA3.1-p53 [40] and
either 10 mg of empty vector (pCMV-myc) or 10 mg of pCANmyc
plasmid expressing WT USP7, C223S, USP7-CTD or USP7-
NTD. 24 hours post- transfection cells were lysed in RIPA buffer
(20 mM Tris pH 8.0, 150 mM NaCl, 1% NP40, 0.1% Sodium
Deoxycholate, 1 mM PMSF) containing protease inhibitor
cocktail (Sigma, P8340) and clarified by centrifugation at
15,000 rpm at 4uC. For the p21 blot, 60 mg of total protein was
subjected SDS-PAGE and western blotting, whereas 25 mg was
used for all other blots. Membranes were blocked in blocking
buffer (5% milk in PBS (137 mM NaCl, 2.7 mM KCl, 0.01 mM
Na2HPO4, 1.4 mM KH2PO4, pH 7.4)). Primary antibodies used
were R2B2 for USP7 [29], DO-1 for p53 (Santa Cruz), Ab-1 for
Actin (Calbiochem), antibody 187 for p21 (Santa Cruz, sc-817)
and antibody A-14 for c-myc (Santa Cruz, sc-789). After primary
antibody incubation, membranes were washed in PBS with 0.1%
Tween 20 (PBS-T) then incubated with the secondary antibodies
goat anti mouse-HRP (Santa Cruz, SC-2055) or goat anti-rabbit-
HRP (Santa Cruz, SC-2004). Following washes in PBS-T, blots
were developed using chemiluminescence ECL reagent (Perkin
Elmer).
Chromatin Immunoprecipitation (ChIP)
H1299 cells in 10 cm dishes at 80% confluency were transfected
with 4 mg of a plasmid expressing p53, 13 mg of vector expressing
USP7 or C223S, or an empty vector. 24 hours post-transfection,
cells were fixed with 1% formaldehyde, lysed in RIPA buffer
containing protease inhibitor cocktail (Sigma, P8340) and
sonicated briefly to shear the DNA. Clarified lysates were
precleared with Protein A/G beads (Santa Cruz, SC-2003) and
normal mouse IgG (Santa Cruz, SC-2343) prior to immunopre-
cipitation with p53 DO1 antibody (Santa Cruz). Protein cross links
were reversed in the immunoprecipitated DNA by incubating at
65uC for 16 hrs. DNA was purified using QIAquick Gel
Extraction Kit (Qiagen, 28704) and analyzed by quantitative
RT-PCR using LightyCycler 480 DNA SYBR Green I Master
(Roche, 04707516001) and a Rotorgene Q-PCR system (Corbett
Research). Primers used for quantification were as follows: p21
(Forward: 59CTGGACTGGGCACTCTTGTC 39, Reverse:
59CTCCTACCATCCCCTTCCTC 39); Mdm2 (Forward 59GG-
ATTGGGCCGGTTCAGTGG 39, Reverse 59GCGTCCGTGC-
CCACAGGTC 39); BAX (Forward 59TATCTCTTGGGCT-
CACAAG 39, Reverse 59ACTGTCCAATGAGCATCTCC 39);
PIG3 (Forward 59GATCCCAGGACTGCGTTTTGCC 39, Re-
verse 59GGGAACGAGACCCAACCTCTTG 39) and GAPDH
(Forward, 59TGTTGCCATCAATGACCCCTT 39 Reverse 59C-
TCCACGACGTACTCAGCG 39). Lysates used for chromatin
immunoprecipitation were also subjected to SDS-PAGE and
western blotting using antibodies indicated in the results section.
ChIP signal was normalized to p53 levels as determined by
Western blots developed using the ECL Plus system (GE
Amersham) and quantified on a Typhoon Imaging scanner using
ImageQuant 5.0 software.
Luciferase Assay
H1299 cells in 6 cm dishes were grown to 80% confluence and
transfected with 0.5 mg of a plasmid containing the luciferase
reporter gene fused to p53 specific sequences from the p21
promoter (p21-Luc) [41], 0.01 mg pCDNA3.1-p53 expressing p53
[40] (both plasmids kindly provided by Dr Sam Benchimol) and
4 mg of a either plasmid expressing the USP7-CTD or empty
plasmid. 24 hours post-transfection, cells were moved to 10 cm
dishes. Cells were harvested 48 hours post-transfection and
processed for luciferase assay according to the Promega Luciferase
Assay System (E1500). Luciferase activity was measured by the
Molecular Devices Spectramax M2E and analyzed by using the
Softmax Pro software v5.0.1. Results from at least 3 independent
experiments are reported.
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